The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial showed that death from cardiovascular causes occurred in fewer patients in the GLP-1 analogue liraglutide group compared to the placebo group in patients with T2D and high cardiovascular risk. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.